Anzeige
Mehr »
Login
Freitag, 21.01.2022 Börsentäglich über 12.000 News von 667 internationalen Medien
Innocan Pharma: Ist das die beste CBD-Biotech-Aktie nach GW Pharma?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 603035 ISIN: US0042251084 Ticker-Symbol: DR6 
Tradegate
19.01.22
20:36 Uhr
19,275 Euro
+0,255
+1,34 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
ACADIA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ACADIA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
19,33019,41517:23
19,33019,43017:23

Aktuelle News zur ACADIA PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.01.Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why1
11.01.Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies1
10.01.JPM 2022: Acadia to Stoke up pipeline with $60M central nervous system research pact2
ACADIA PHARMACEUTICALS Aktie jetzt für 0€ handeln
05.01.What 17 Analyst Ratings Have To Say About ACADIA Pharmaceuticals2
22.12.21Why Acadia Pharmaceuticals Stock Climbed More Than 10% Wednesday4
21.12.21Why did Acadia Pharmaceuticals stock dive today? Plans for NUPLAZID label expansion17
21.12.21What Analysts Have To Say On Acadia's Narrower Nuplazid Label Expansion Bid7
21.12.21Acadia Slims Nuplazid Label Expansion Application For Alzheimer's Disease Psychosis5
21.12.21ACADIA price target raised at Citi; says cautiously optimistic on plans for NUPLAZID8
21.12.21ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA5
21.12.21Acadia slims Nuplazid label expansion bid in hopes of clinching Alzheimer's dementia nod without extra studies11
21.12.21General Mills, ACADIA Pharmaceuticals, CytomX Therapeutics among premarket losers' pack18
14.12.21ACADIA PHARMACEUTICALS INC - 8-K, Current Report5
14.12.21Acadia Pharmaceuticals promotes Mark Schneyer to EVP CFO1
07.12.21ACADIA's (ACAD) Rett Syndrome Candidate Meets Goal in Study4
07.12.21Acadia touts late-stage win for its Rett syndrome drug, edging out a lead against its competitors2
07.12.21What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals1
07.12.21Why Acadia Pharmaceuticals Stock Is Rocketing Today9
07.12.21Acadia Pharma extends gains as Wall Street welcomes trial data in Rett syndrome-
07.12.21Acadia Pharma Jumps After Rett Syndrome Candidate Aces Phase 3 Study1
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1